Crispr Therapeutics shares tumble after significant earnings miss
NEW YORK - McKesson Corporation (NYSE:MCK) shares gained 2.8% after the healthcare services company reported better-than-expected fourth-quarter earnings and announced plans to separate its Medical-Surgical Solutions segment.
McKesson posted adjusted earnings per share of $10.12 for the quarter ended March 31, 2025, surpassing analyst estimates of $9.81. Revenue came in at $90.82 billion, up 19% YoY but below the consensus forecast of $93.48 billion.
For the full fiscal year 2025, McKesson reported consolidated revenues of $359.1 billion, a 16% increase from the previous year. Adjusted earnings per diluted share rose 20% to $33.05.
The company provided fiscal 2026 adjusted EPS guidance of $36.75 to $37.55, indicating 11% to 14% growth compared to fiscal 2025. The midpoint of $37.15 is slightly above the analyst consensus of $36.83.
"McKesson delivered strong fourth quarter performance reporting revenue growth of 19% and Adjusted Earnings per Diluted Share growth of 64%," said CEO Brian Tyler. "This marks another year of strong financial results, above our long-term targets, underpinned by operational execution against our strategic priorities."
In a significant strategic move, McKesson announced its intention to separate its Medical-Surgical Solutions segment into an independent company. The company believes this separation will enhance strategic opportunities and operational focus for both entities while unlocking shareholder value.
McKesson also updated its long-term adjusted segment operating profit growth target for U.S. Pharmaceutical (TADAWUL:2070) from 5-7% to 6-8%, reflecting confidence in its core business.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.